▶주메뉴 바로가기
▶본문 바로가기
For most of his life, cardiologist Chang Hyoung-woo treated his obesity with the familiar prescription of diet, exercise and willpower. He even underwent surgery, losing 26 kilograms — only to regain nearly half of it. After his experience with a new generation of obesity drugs, Chang, 46, now argues that people with severe obesity should be offered medication as a primary treatment rather than being expected to rely on lifestyle changes alone. “For patients with severe obesity, diet and exercis
Daewoong Pharmaceutical has received a patent allowance from the US Patent and Trademark Office for an ionizable lipid technology used in its eTurna messenger RNA delivery platform. The allowance indicates that the patent application has been approved, although Daewoong must complete additional procedures before the patent is formally registered and enforceable in the US. The patent covers ionizable lipids used to form lipid nanoparticles. The nanoparticles are used to encapsulate mRNA strands t
Celltrion said Friday it has launched the intravenous formulation of SteQeyma for autoimmune diseases in Japan. Celltrion launched the IV formulation about four months after receiving approval from Japan’s Ministry of Health, Labour and Welfare in April. In addition to its existing indications for psoriasis and psoriatic arthritis, the product now also covers Crohn’s disease, significantly expanding its treatment scope. Celltrion’s Japanese subsidiary plans to leverage its sales expertise built
SK Biopharmaceuticals said Wednesday it has reached a settlement with Indian generic drugmaker MSN Laboratories in a United States patent dispute over cenobamate, its epilepsy treatment sold as Xcopri in the US, laying the groundwork for continued patent protection for the drug in the world’s largest pharmaceutical market. Although the terms of the agreement were not disclosed, it marks the first resolution in SK Biopharmaceuticals’ strategy to defend Xcopri’s intellectual property rights agains
Celltrion’s record second-quarter results have prompted a wave of target-price upgrades from Korean and global brokerages, with analysts highlighting its fast-growing portfolio and improving profitability. The Korean biopharmaceutical company reported quarterly sales of 1.4 trillion won ($990 million), beating market expectations and setting a record for the second consecutive quarter. Operating profit surged 86.3 percent on-year to 451.8 billion won, lifting its operating margin to 32.4 percent
Korean biotechnology firm Alteogen said Wednesday it has signed an exclusive licensing agreement worth up to $365 million with a global pharmaceutical company. Under the deal, the latter will develop and commercialize subcutaneous formulations of biologic drugs using Alteogen's proprietary recombinant human hyaluronidase platform ALT-B4. Also known by its generic name berahyaluronidase alfa, ALT-B4 is Alteogen's proprietary recombinant human hyaluronidase developed using the company's Hybrozyme
Matica Biotechnology is positioning Korea as a strategic destination for investigator-initiated trials, or IITs, by offering an integrated platform that combines manufacturing, clinical development and regulatory support. The move comes as global drugmakers are diversifying manufacturing and clinical development away from China amid rising geopolitical tensions. According to Matica Biotechnology — the US-based contract development and manufacturing subsidiary of Korea’s Cha Biotech — on Sunday,
Daewoong Pharmaceutical's botulinum toxin brand Nabota has entered Kuwait, expanding its presence to seven Middle Eastern markets while setting a record among Korean botulinum toxin makers in the region. According to Daewoong Pharmaceutical on Thursday, it began supplying Nabota to Kuwait earlier this month on top of its existing market lineup of Saudi Arabia, the United Arab Emirates, Turkiye, Qatar, Egypt and Bahrain in the Middle East. With the latest expansion, Daewoong underscored that Nabo
Yuhan said Thursday it has launched its blood sugar management probiotic DangQLac, sold locally as Glucobiotic, in Mexico as part of its push into the Latin American dietary supplement market. DangQLac contains Lactiplantibacillus plantarum HAC01, the first probiotic strain in Korea to receive approval from the Ministry of Food and Drug Safety for its post-meal blood sugar-lowering functionality, as its main ingredient. According to the company, an eight-week human clinical trial showed statisti
Celltrion said Wednesday it expects a series of key research and clinical milestones over the next year. Preclinical data for its next-generation obesity treatment is due later this year, and initial clinical results from several oncology drug candidates are scheduled for the first half of next year. According to Celltrion, it plans to disclose preclinical findings for its world's first quad-agonist obesity drug candidate CT-G32 in November and submit an investigational new drug, or IND, applica
Chipotle bets on Korea for first bite of Asia
Samsung vs. LG battle for AI cooling heats up
Musinsa posts record earnings on offline, global expansion
One purchase every 0.9 second: Olive Young foreign sales top W1tr
Samsung, SK hynix tax payments surge 167% on chip boom
SK Chemicals eyes European can-coating market
Sept. 2, 2026
Aug. 31, 2026
Aug. 27, 2026
Aug. 21, 2026
Aug. 19, 2026
Aug. 6, 2026
Aug. 6, 2026
Aug. 2, 2026
July 30, 2026
July 30, 2026
July 29, 2026
